Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma in Relapse
Multiple Myeloma, Refractory

Interventions: Drug: Isatuximab
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2020-02-27

Last Posted Date: 2023-01-10

Lead Sponsor: Poitiers University Hospital

Target Recruit Count: 82

Registration Number: NCT04287855

Locations: 🇫🇷
CHU Poitiers, Poitiers, France

Comparative Effectiveness of Particulate Versus Nonparticulate Steroid Injections for Musculoskeletal Conditions

Phase 4

Completed

Conditions: Impingement Shoulder
Osteoarthritis
Tendinopathy

Interventions: Drug: Triamcinolone or Betamethasone
Drug: Dexamethasone

First Posted Date: 2020-02-20

Last Posted Date: 2024-11-22

Lead Sponsor: Stanford University

Target Recruit Count: 165

Registration Number: NCT04278833

Locations: 🇺🇸
Stanford University, Redwood City, California, United States

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Phase 1

Terminated

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2020-02-17

Last Posted Date: 2020-03-17

Lead Sponsor: Takeda

Target Recruit Count: 14

Registration Number: NCT04272775

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Isatuximab SAR650984
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Montelukast or equivalent
Drug: Acetaminophen
Drug: Diphenhydramine or equivalent
Drug: Methylprednisolone or equivalent

First Posted Date: 2020-02-17

Last Posted Date: 2024-10-31

Lead Sponsor: Sanofi

Target Recruit Count: 337

Registration Number: NCT04270409

Locations: 🇦🇺
Investigational Site Number :0360008, Liverpool, New South Wales, Australia
🇯🇵
Investigational Site Number :3920001, Shibuya-ku, Tokyo, Japan
🇱🇹
Investigational Site Number :4400001, Vilnius, Lithuania

and more 102 locations

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2

Recruiting

Conditions: AL Amyloidosis
Amyloid
Refractory AL Amyloidosis

Interventions: Drug: Daratumumab SC
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2020-02-17

Last Posted Date: 2024-06-26

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 21

Registration Number: NCT04270175

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸
Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 1 locations

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2

Withdrawn

Conditions: Lung Squamous Cell Carcinoma
Recurrent Lung Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Dexamethasone
Drug: Docetaxel
Biological: Ramucirumab
Drug: Sapanisertib

First Posted Date: 2020-02-13

Last Posted Date: 2020-11-20

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT04267913

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Carfilzomib
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Montelukast
Drug: Daratumumab
Biological: Autologous Stem Cell Transplant (ASCT)

First Posted Date: 2020-02-13

Last Posted Date: 2024-06-14

Lead Sponsor: University of Miami

Target Recruit Count: 306

Registration Number: NCT04268498

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 6 locations

Restrictive Use of Dexamethasone in Glioblastoma

Not Applicable

Recruiting

Conditions: Glioblastoma
Dexamethasone
Steroids

Interventions: Drug: Dexamethasone

First Posted Date: 2020-02-12

Last Posted Date: 2024-05-08

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 50

Registration Number: NCT04266977

Locations: 🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭
Universitätsspital Zürich, Zürich, Switzerland
🇨🇭
Kantonsspital St. Gallen, Saint Gallen, St.Gallen, Switzerland

and more 1 locations

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Phase 2

Active, not recruiting

Conditions: Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8
Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Liver and Intrahepatic Bile Duct Carcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Unresectable Intrahepatic Cholangiocarcinoma